Abstract
Acetylation of the ɛ-amino group of a lysine residue was first discovered with histones in 1968, but the responsible enzymes, histone acetyltransferases and deacetylases, were not identified until the mid-1990s. In the past decade, knowledge about this modification has exploded, with targets rapidly expanding from histones to transcription factors and other nuclear proteins, and then to cytoskeleton, metabolic enzymes, and signaling regulators in the cytoplasm. Thus, protein lysine acetylation has emerged as a major post-translational modification to rival phosphorylation. In this issue of Oncogene, 19 articles review various aspects of the enzymes governing lysine acetylation, especially about their intimate links to cancer. To introduce the articles, we highlight here four central themes: (i) multisubunit enzymatic complexes; (ii) non-histone substrates in diverse cellular processes; (iii) interplay of lysine acetylation with other regulatory mechanisms, such as noncoding RNA-mediated gene silencing and activation; and (iv) novel therapeutic strategies and preventive measures to combat cancer and other human diseases.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Acute myeloid leukemia with rare recurring translocations—an overview of the entities included in the international consensus classification
Annals of Hematology Open Access 06 March 2024
-
Upregulation of HDAC9 in hippocampal neurons mediates depression-like behaviours by inhibiting ANXA2 degradation
Cellular and Molecular Life Sciences Open Access 10 September 2023
-
A complex network of transcription factors and epigenetic regulators involved in bovine leukemia virus transcriptional regulation
Retrovirology Open Access 02 June 2023
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Adams CC, Workman JL . (1993). Nucleosome displacement in transcription. Cell 72: 305–308.
Ahn SH, Diaz RL, Grunstein M, Allis CD . (2006). Histone H2B deacetylation at lysine 11 is required for yeast apoptosis induced by phosphorylation of H2B at serine 10. Mol Cell 24: 211–220.
Allard S, Utley RT, Savard J, Clarke A, Grant P, Brandl CJ et al. (1999). NuA4, an essential transcription adaptor/histone H4 acetyltransferase complex containing Esa1p and the ATM-related cofactor Tra1p. EMBO J 18: 5108–5119.
Allfrey V, Faulkner RM, Mirsky AE . (1964). Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis. Proc Natl Acad Sci USA 51: 786–794.
Aufsatz W, Stoiber T, Rakic B, Naumann K . (2007). Arabidopsis histone deacetylase 6: a green link to RNA silencing. Oncogene 26: 5477–5488.
Avvakumov N, Côté J . (2007). The MYST family of histone acetyltransferases and their intimate links to cancer. Oncogene 26: 5395–5407.
Baker SP, Grant PA . (2007). The SAGA continues: expanding the cellular role of a transcriptional co-activator complex. Oncogene 26: 5329–5340.
Balasubramanyam K, Varier RA, Altaf M, Swaminathan V, Siddappa NB, Ranga U et al. (2004). Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J Biol Chem 279: 51163–51171.
Bannister AJ, Kouzarides T . (1996). The CBP co-activator is a histone acetyltransferase. Nature 384: 641–643.
Becker PB . (1994). The establishment of active promoters in chromatin. Bioessays 16: 541–547.
Belfield JL, Whittaker C, Cader MZ, Chawla S . (2006). Differential effects of Ca2+ and cAMP on transcription mediated by MEF2D and cAMP-response element-binding protein in hippocampal neurons. J Biol Chem 281: 27724–27732.
Berdeaux R, Goebel N, Banaszynski L, Takemori H, Wandless T, Shelton GD et al. (2007). SIK1 is a class II HDAC kinase that promotes survival of skeletal myocytes. Nat Med 13: 597–603.
Blander G, Guarente L . (2004). The Sir2 family of protein deacetylases. Annu Rev Biochem 73: 417–435.
Borrow J, Stanton Jr VP, Andresen JM, Becher R, Behm FG, Chaganti RS et al. (1996). The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. Nat Genet 14: 33–41.
Boyault C, Sadoul K, Pabion M, Khochbin S . (2007). HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination. Oncogene 26: 5468–5476.
Brownell JE, Allis CD . (1995). An activity gel assay detects a single, catalytically active histone acetyltransferase subunit in Tetrahymena macronuclei. Proc Natl Acad Sci USA 92: 6364–6368.
Brownell JE, Zhou J, Ranalli T, Kobayashi R, Edmondson DG, Roth SY et al. (1996). Tetrahymena histone acetyltransferase A: a homolog to yeast Gcn5p linking histone acetylation to gene activation. Cell 84: 843–851.
Brush MH, Guardiola A, Connor JH, Yao TP, Shenolikar S . (2004). Deactylase inhibitors disrupt cellular complexes containing protein phosphatases and deacetylases. J Biol Chem 279: 7685–7691.
Candido EP, Reeves R, Davie JR . (1978). Sodium butyrate inhibits histone deacetylation in cultured cells. Cell 14: 105–113.
Canettieri G, Morantte I, Guzman E, Asahara H, Herzig S, Anderson SD et al. (2003). Attenuation of a phosphorylation-dependent activator by an HDAC–PP1 complex. Nat Struct Biol 10: 175–181.
Chen Y, Sprung R, Tang Y, Ball H, Sangras B, Kim S et al. (2007). Lysine propionylation and butyrylation are novel post-translational modifications in histones. Mol Cell Proteomics 6: 812–819.
Chinenov Y . (2002). A second catalytic domain in the Elp3 histone acetyltransferases: a candidate for histone demethylase activity? Trends Biochem Sci 27: 115–117.
Cohen T, Yao TP . (2004). AcK-knowledge reversible acetylation. Sci STKE, pe42.
Collins SR, Miller KM, Maas NL, Roguev A, Fillingham J, Chu CS et al. (2007). Functional dissection of protein complexes involved in yeast chromosome biology using a genetic interaction map. Nature 446: 806–810.
Cress WD, Seto E. (2000). Histone deacetylases, transcriptional control, and cancer. J Cell Physiol 184: 1–16.
Denslow SA, Wade PA . (2007). The human Mi-2/NuRD complex and gene regulation. Oncogene 26: 5433–5438.
Dequiedt F, Kasler H, Fischle W, Kiermer V, Weinstein M, Herndier BG et al. (2003). HDAC7, a thymus-specific class II histone deacetylase, regulates Nur77 transcription and TCR-mediated apoptosis. Immunity 18: 687–698.
Doyon Y, Cote J . (2004). The highly conserved and multifunctional NuA4 HAT complex. Curr Opin Genet Dev 14: 147–154.
Driscoll R, Hudson A, Jackson SP . (2007). Yeast Rtt109 promotes genome stability by acetylating histone H3 on lysine 56. Science 315: 649–652.
Druesne N, Pagniez A, Mayeur C, Thomas M, Cherbuy C, Duee PH et al. (2004). Diallyl disulfide (DADS) increases histone acetylation and p21(waf1/cip1) expression in human colon tumor cell lines. Carcinogenesis 25: 1227–1236.
Earley K, Lawrence RJ, Pontes O, Reuther R, Enciso AJ, Silva M et al. (2006). Erasure of histone acetylation by Arabidopsis HDA6 mediates large-scale gene silencing in nucleolar dominance. Genes Dev 20: 1283–1293.
Gershey EL, Vidali G, Allfrey VG . (1968). Chemical studies of histone acetylation. The occurrence of epsilon-N-acetyllysine in the f2a1 histone. J Biol Chem 243: 5018–5022.
Glozak MA, Seto E . (2007). Histone deacetylases and cancer. Oncogene 26: 5420–5432.
Goldberg AD, Allis CD, Bernstein E . (2007). Epigenetics: a landscape takes shape. Cell 128: 635–638.
Goodman RH, Smolik S . (2000). CBP/p300 in cell growth, transformation, and development. Genes Dev 14: 1553–1577.
Grant PA, Schieltz D, Pray-Grant MG, Yates JR, Workman JL . (1998). The ATM-related cofactor Tra1 is a component of the purified SAGA complex. Mol Cell 2: 863–867.
Grégoire S, Xiao L, Nie J, Xu M, Wong J, Seto E et al. (2007). Histone deacetylase 3 interacts and deacetylates MEF2 transcription factors. Mol Cell Biol 27: 1280–1295.
Gregoretti IV, Lee YM, Goodson HV . (2004). Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol 338: 17–31.
Grossman SR, Deato ME, Brignone C, Chan HM, Kung AL, Tagami H et al. (2003). Polyubiquitination of p53 by a ubiquitin ligase activity of p300. Science 300: 342–344.
Grozinger CM, Schreiber SL . (2002). Deacetylase enzymes: biological functions and the use of small-molecule inhibitors. Chem Biol 9: 3–16.
Gu W, Roeder RG . (1997). Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90: 595–606.
Hallows WC, Lee S, Denu JM . (2006). Sirtuins deacetylate and activate mammalian acetyl-CoA synthetases. Proc Natl Acad Sci USA 103: 10230–10235.
Han J, Zhou H, Horazdovsky B, Zhang K, Xu RM, Zhang Z . (2007). Rtt109 acetylates histone H3 lysine 56 and functions in DNA replication. Science 315: 653–655.
Hansen JC, Ausio J . (1992). Chromatin dynamics and the modulation of genetic activity. Trends Biochem Sci 17: 187–191.
Hodawadekar SC, Marmorstein R . (2007). Chemistry of acetyl transfer by histone modifying enzymes: structure, mechanism and implications for effector design. Oncogene 26: 5528–5540.
Humphrey GW, Wang Y, Russanova VR, Hirai T, Qin J, Nakatani Y et al. (2001). Stable histone deacetylase complexes distinguished by the presence of SANT domain proteins CoREST/kiaa0071 and Mta-L1. J Biol Chem 276: 6812–6824.
Ikura T, Ogryzko VV, Grigoriev M, Groisman R, Wang J, Horikoshi M et al. (2000). Involvement of the TIP60 histone acetylase complex in DNA repair and apoptosis. Cell 102: 463–473.
Imhof A, Yang X-J, Ogryzko VV, Nakatani Y, Wolffe AP, Ge H . (1997). Acetylation of general transcription factors by histone acetyltransferases. Curr Biol 7: 689–692.
Ito K, Ito M, Elliott WM, Cosio B, Caramori G, Kon OM et al. (2005). Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 352: 1967–1976.
Ivanov D, Schleiffer A, Eisenhaber F, Mechtler K, Haering CH, Nasmyth K . (2002). Eco1 is a novel acetyltransferase that can acetylate proteins involved in cohesion. Curr Biol 12: 323–328.
Iwabata H, Yoshida M, Komatsu Y . (2005). Proteomic analysis of organ-specific post-translational lysine-acetylation and -methylation in mice by use of anti-acetyllysine and -methyllysine mouse monoclonal antibodies. Proteomics 5: 4653–4664.
Iwata A, Riley BE, Johnston JA, Kopito RR . (2005). HDAC6 and microtubules are required for autophagic degradation of aggregated huntingtin. J Biol Chem 280: 40282–40292.
Jenuwein T, Allis CD . (2001). Translating the histone code. Science 293: 1074–1080.
Kamine J, Elangovan B, Subramanian T, Coleman D, Chinnadurai G . (1996). Identification of a cellular protein that specifically interacts with the essential cysteine region of the HIV-1 Tat transactivator. Virology 216: 357–366.
Karagianni P, Wong J . (2007). HDAC3: taking the SMRT-N-CoRrect road to repression. Oncogene 26: 5439–5449.
Kawaguchi Y, Kovacs JJ, McLaurin A, Vance JM, Ito A, Yao TP . (2003). The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 115: 727–738.
Kim SC, Sprung R, Chen Y, Xu Y, Ball H, Pei J et al. (2006). Substrate and functional diversity of lysine acetylation revealed by a proteomics survey. Mol Cell 23: 607–618.
Kleff S, Andrulis ED, Anderson CW, Sternglanz R . (1995). Identification of a gene encoding a yeast histone H4 acetyltransferase. J Biol Chem 270: 24674–24677.
Koo SH, Flechner L, Qi L, Zhang X, Screaton RA, Jeffries S et al. (2005). The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature 437: 1109–1111.
Kouzarides T . (2000). Acetylation: a regulatory modification to rival phosphorylation? EMBO J 19: 1176–1179.
Kouzarides T . (2007). Chromatin modifications and their function. Cell 128: 693–705.
Lafon A, Chang CS, Scott EM, Jacobson SJ, Pillus L . (2007). MYST opportunities for growth control: yeast genes illuminate human cancer gene functions. Oncogene 26: 5373–5384.
Lanz RB, McKenna NJ, Onate SA, Albrecht U, Wong J, Tsai SY et al. (1999). A steroid receptor coactivator, SRA, functions as an RNA and is present in an SRC-1 complex. Cell 97: 17–27.
Lee KK, Workman JL . (2007). Histone acetyltransferase complexes: one size doesn't fit all. Nat Rev Mol Cell Biol 8: 284–295.
Lee MG, Wynder C, Cooch N, Shiekhattar R . (2005). An essential role for CoREST in nucleosomal histone 3 lysine 4 demethylation. Nature 437: 432–435.
L'Hernault SW, Rosenbaum JL . (1985). Chlamydomonas alpha-tubulin is posttranslationally modified by acetylation on the epsilon-amino group of a lysine. Biochemistry 24: 473–478.
Li B, Carey M, Workman JL . (2007). The role of chromatin during transcription. Cell 128: 707–719.
Li Y, Kao GD, Garcia BA, Shabanowitz J, Hunt DF, Qin J et al. (2006). A novel histone deacetylase pathway regulates mitosis by modulating Aurora B kinase activity. Genes Dev 20: 2566–2579.
Lin W, Dent SY . (2006). Functions of histone-modifying enzymes in development. Curr Opin Genet Dev 16: 137–142.
Linares LK, Kiernan R, Triboulet R, Chable-Bessia C, Latreille D, Cuvier O et al. (2007). Intrinsic ubiquitination activity of PCAF controls the stability of the oncoprotein Hdm2. Nat Cell Biol 9: 331–338.
Liu L, Scolnick DM, Trievel RC, Zhang HB, Marmorstein R, Halazonetis TD et al. (1999). p53 Sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage. Mol Cell Biol 19: 1202–1909.
Lucchesi JC, Kelly WG, Panning B . (2005). Chromatin remodeling in dosage compensation. Annu Rev Genet 39: 615–651.
Marchion D, Munster P . (2007). Development of histone deacetylase inhibitors for cancer treatment. Expert Rev Anticancer Ther 7: 583–598.
Martin M, Kettmann R, Dequiedt F . (2007). Class IIa histone deacetylases: regulating the regulators. Oncogene 26: 5450–5467.
McMahon SB, Buskirk HAV, Dugan KA, Copeland TD, Cole MD . (1998). The novel ATM-related protein TRRAP is an essential cofactor for the c-Myc and E2F oncoproteins. Cell 94: 363–374.
Mejat A, Ramond F, Bassel-Duby R, Khochbin S, Olson EN, Schaeffer L . (2005). Histone deacetylase 9 couples neuronal activity to muscle chromatin acetylation and gene expression. Nat Neurosci 8: 313–321.
Minucci S, Pelicci PG . (2006). Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6: 38–51.
Mittal R, Peak-Chew SY, McMahon HT . (2006). Acetylation of MEK2 and I kappa B kinase (IKK) activation loop residues by YopJ inhibits signaling. Proc Natl Acad Sci USA 103: 18574–18579.
Mizzen CA, Yang XJ, Kokubo T, Brownell JE, Bannister AJ, Owen-Hughes T et al. (1996). The TAF(II)250 subunit of TFIID has histone acetyltransferase activity. Cell 87: 1261–1270.
Mujtaba S, Zeng L, Zhou M-M . (2007). Structure and acetyl-lysine recognition of the bromodomain. Oncogene 26: 5521–5527.
Mukherjee S, Keitany G, Li Y, Wang Y, Ball HL, Goldsmith EJ et al. (2006). Yersinia YopJ acetylates and inhibits kinase activation by blocking phosphorylation. Science 312: 1211–1214.
Murr R, Vaissière T, Sawan C, Shukla V, Herceg Z . (2007). Orchestration of chromatin-based processes: mind the TRRAP. Oncogene 26: 5358–5372.
Myzak MC, Karplus PA, Chung FL, Dashwood RH . (2004). A novel mechanism of chemoprotection by sulforaphane: inhibition of histone deacetylase. Cancer Res 64: 5767–5774.
Nagy Z, Tora L . (2007). Distinct GCN5/PCAF-containing complexes function as co-activators and are involved in transcription factor and global histone acetylation. Oncogene 26: 5341–5357.
Nicolas E, Yamada T, Cam HP, Fitzgerald PC, Kobayashi R, Grewal SI . (2007). Distinct roles of HDAC complexes in promoter silencing, antisense suppression and DNA damage protection. Nat Struct Mol Biol 14: 372–380.
Ogryzko VV, Schiltz RL, Russanova V, Howard BH, Nakatani Y . (1996). The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 87: 953–959.
Okamoto M, Takemori H, Katoh Y . (2004). Salt-inducible kinase in steroidogenesis and adipogenesis. Trends Endocrinol Metab 15: 21–26.
Paranjape SM, Kamakaka RT, Kadonaga JT . (1994). Role of chromatin structure in the regulation of transcription by RNA polymerase II. Annu Rev Biochem 63: 265–297.
Parthun MR . (2007). Hat1: the emerging cellular roles of a type B histone acetyltransferase. Oncogene 26: 5319–5328.
Parthun MR, Widom J, Gottschling DE . (1996). The major cytoplasmic histone acetyltransferase in yeast: links to chromatin replication and histone metabolism. Cell 87: 85–94.
Peterson CL, Tamkun JW . (1995). The SWI–SNF complex: a chromatin remodeling machine? Trends Biochem Sci 20: 143–146.
Phillips DM . (1963). The presence of acetyl groups of histones. Biochem J 87: 258–263.
Piperno G, Fuller MT . (1985). Monoclonal antibodies specific for an acetylated form of alpha-tubulin recognize the antigen in cilia and flagella from a variety of organisms. J Cell Biol 101: 2085–2094.
Rasheed WK, Johnstone RW, Prince HM . (2007). Histone deacetylase inhibitors in cancer therapy. Expert Opin Investig Drugs 16: 659–678.
Rea S, Xouri G, Akhtar A . (2007). Males absent on the first (MOF): from flies to humans. Oncogene 26: 5385–5394.
Reifsnyder C, Lowell J, Clarke A, Pillus L . (1996). Yeast SAS silencing genes and human genes associated with AML and HIV-1 Tat interactions are homologous with acetyltransferases. Nat Genet 14: 42–49.
Richon VM, Emiliani S, Verdin E, Webb Y, Breslow R, Rifkind RA et al. (1998). A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci USA 95: 3003–3007.
Riggs MG, Whittaker RG, Neumann JR, Ingram VM . (1977). n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells. Nature 268: 462–464.
Ropero S, Fraga MF, Ballestar E, Hamelin R, Yamamoto H, Boix-Chornet M et al. (2006). A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat Genet 38: 566–569.
Roth SY, Denu JM, Allis CD . (2001). Histone acetyltransferases. Annu Rev Biochem 70: 81–120.
Rundlett SE, Carmen AA, Kobayashi R, Bavykin S, Turner BM, Grunstein M . (1996). HDA1 and RPD3 are members of distinct yeast histone deacetylase complexes that regulate silencing and transcription. Proc Natl Acad Sci USA 93: 14503–14508.
Sakaguchi K, Herrera JE, Saito S, Miki T, Bustin M, Vassilev A et al. (1998). DNA damage activates p53 through a phosphorylation–acetylation cascade. Genes Dev 12: 2831–2841.
Saleh A, Schieltz D, Ting N, McMahon SB, Litchfield DW, Yates JR et al. (1998). Tra1p is a component of the yeast Ada.Spt transcriptional regulatory complexes. J Biol Chem 273: 26559–26565.
Saunders LR, Verdin E . (2007). Sirtuins: critical regulators at the crossroads between cancer and aging. Oncogene 26: 5489–5504.
Schwer B, Bunkenborg J, Verdin RO, Andersen JS, Verdin E . (2006). Reversible lysine acetylation controls the activity of the mitochondrial enzyme acetyl-CoA synthetase 2. Proc Natl Acad Sci U S A 103: 10224–10229.
Sealy L, Chalkley R . (1978). The effect of sodium butyrate on histone modification. Cell 14: 115–121.
Seet BT, Dikic I, Zhou MM, Pawson T . (2006). Reading protein modifications with interaction domains. Nat Rev Mol Cell Biol 7: 473–483.
Shahbazian MD, Grunstein M . (2007). Functions of site-specific histone acetylation and deacetylation. Annu Rev Biochem 76: 26.1–26.26.
Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA, et al. (2004). Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 119: 941–953.
Starai VJ, Celic I, Cole RN, Boeke JD, Escalante-Semerena JC . (2002). Sir2-dependent activation of acetyl-CoA synthetase by deacetylation of active lysine. Science 298: 2390–2392.
Sterner DE, Berger SL . (2000). Acetylation of histones and transcription-related factors. Microbiol Mol Biol Rev 64: 435–459.
Sterner R, Vidali G, Allfrey VG . (1979). Studies of acetylation and deacetylation in high mobility group proteins. Identification of the sites of acetylation in HMG-1. J Biol Chem 254: 11577–11583.
Straub T, Becker PB . (2007). Dosage compensation: the beginning and end of generalization. Nat Rev Genet 8: 47–57.
Sykes SM, Mellert HS, Holbert MA, Li K, Marmorstein R, Lane WS et al. (2006). Acetylation of the p53 DNA-binding domain regulates apoptosis induction. Mol Cell 24: 841–851.
Tahiliani M, Mei P, Fang R, Leonor T, Rutenberg M, Shimizu F et al. (2007). The histone H3K4 demethylase SMCX links REST target genes to X-linked mental retardation. Nature 447: 601–605.
Tang Y, Luo J, Zhang W, Gu W . (2006). Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis. Mol Cell 24: 827–839.
Taunton J, Hassig CA, Schreiber SL . (1996). A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science 272: 408–411.
Toleman C, Paterson AJ, Whisenhunt TR, Kudlow JE . (2004). Characterization of the histone acetyltransferase (HAT) domain of a bifunctional protein with activable O-GlcNAcase and HAT activities. J Biol Chem 279: 53665–53673.
Trivedi CM, Luo Y, Yin Z, Zhang M, Zhu W, Wang T et al. (2007). Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3beta activity. Nat Med 13: 324–331.
Tsubota T, Berndsen CE, Erkmann JA, Smith CL, Yang L, Freitas MA et al. (2007). Histone H3-K56 acetylation is catalyzed by histone chaperone-dependent complexes. Mol Cell 25: 703–712.
Turner BM . (1993). Decoding the nucleosome. Cell 75: 5–8.
van der Linden AM, Nolan KM, Sengupta P . (2007). KIN-29 SIK regulates chemoreceptor gene expression via an MEF2 transcription factor and a class II HDAC. EMBO J 26: 358–370.
Vaquero A, Sternglanz R, Reinberg D . (2007). NAD+-dependent deacetylation of H4 lysine 16 by class III HDACs. Oncogene 26: 5505–5520.
Vassilev A, Yamauchi J, Kotani T, Prives C, Avantaggiati ML, Qin J et al. (1998). The 400 kDa subunit of the PCAF histone acetylase complex belongs to the ATM superfamily. Mol Cell 2: 869–875.
Wolffe AP . (1994). Transcription: in tune with the histones. Cell 77: 13–16.
Xhemalce B, Miller KM, Driscoll R, Masumoto H, Jackson SP, Kouzarides T et al. (2007). Regulation of histone H3 lysine 56 acetylation in Schizosaccharomyces pombe. J Biol Chem 282: 15040–15047.
Xie H, Bandhakavi S, Roe MR, Griffin TJ . (2007). Preparative peptide isoelectric focusing as a tool for improving the identification of lysine-acetylated peptides from complex mixtures. J Proteome Res 6: 2019–2026.
Xu WS, Parmigiani RB, Marks PA . (2007). Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26: 5541–5552.
Yamada T, Fischle W, Sugiyama T, Allis CD, Grewal SI . (2005). The nucleation and maintenance of heterochromatin by a histone deacetylase in fission yeast. Mol Cell 20: 173–185.
Yang XJ . (2004). The diverse superfamily of lysine acetyltransferases and their roles in leukemia and other diseases. Nucleic Acids Res 32: 959–976.
Yang WM, Inouye C, Zeng Y, Bearss D, Seto E . (1996a). Transcriptional repression by YY1 is mediated by interaction with a mammalian homolog of the yeast global regulator RPD3. Proc Natl Acad Sci USA 93: 12845–12850.
Yang XJ, Grégoire S . (2007). Metabolism, cytoskeleton and cellular signaling in the grip of protein Nɛ- and O-acetylation. EMBO Rep 8: 556–562.
Yang XJ, Ogryzko VV, Nishikawa J, Howard BH, Nakatani Y . (1996b). A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A. Nature 382: 319–324.
Yang X-J, Ullah M . (2007). MOZ and MORF, two large MYSTic HATs in normal and cancer stem cells. Oncogene 26: 5408–5419.
Yoshida M, Kijima M, Akita M, Beppu T . (1990). Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 265: 17174–17179.
Zaratiegui M, Irvine DV, Martienssen RA . (2007). Noncoding RNAs and gene silencing. Cell 128: 763–776.
Zhang X, Ozawa Y, Lee H, Wen YD, Tan TH, Wadzinski BE, et al. (2005). Histone deacetylase 3 (HDAC3) activity is regulated by interaction with protein serine/threonine phosphatase 4. Genes Dev 19: 827–839.
Zhang Y, LeRoy G, Seelig HP, Lane WS, Reinberg D . (1998). The dermatomyositis-specific autoantigen Mi2 is a component of a complex containing histone deacetylase and nucleosome remodeling activities. Cell 95: 279–289.
Zhu P, Martin E, Mengwasser J, Schlag P, Janssen KP, Gottlicher M . (2004). Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 5: 455–463.
Acknowledgements
We are grateful to Dr Prem Reddy for vision and support, the contributors for enthusiasm and ∼40 anonymous referees for critical evaluation of the articles. We apologize to those whose works are unintentionally omitted in this issue because of knowledge and space limitation. Our research has been supported by grants from the NIH (to ES) and the Canadian funding agencies NCIC, CIHR, CFI and NSERC (to XJY).
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Yang, XJ., Seto, E. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene 26, 5310–5318 (2007). https://doi.org/10.1038/sj.onc.1210599
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1210599
Keywords
This article is cited by
-
Epigenetic modifications in the development of bronchopulmonary dysplasia: a review
Pediatric Research (2024)
-
Acute myeloid leukemia with rare recurring translocations—an overview of the entities included in the international consensus classification
Annals of Hematology (2024)
-
A complex network of transcription factors and epigenetic regulators involved in bovine leukemia virus transcriptional regulation
Retrovirology (2023)
-
Valproic acid inhibits cell growth in both MCF-7 and MDA-MB231 cells by triggering different responses in a cell type-specific manner
Journal of Translational Medicine (2023)
-
Upregulation of HDAC9 in hippocampal neurons mediates depression-like behaviours by inhibiting ANXA2 degradation
Cellular and Molecular Life Sciences (2023)